CT01, a small-molecule glue targeting NEK7 developed by Captor Therapeutics, can induce the degradation of proteins including NEK7, GSPT1, and SALL4 and has been applied to the treatment of hepatocellular carcinoma, lung cancer, and NET tumors [160]. Here, NEK7 is linked to lung carcinoma.